生物制剂治疗结局的性别差异——基于丹麦医疗登记数据库1750例银屑病关节炎患者的研究
男性TNFI中位持续用药时间3.8年(95%CI:3.0,5.7)长于女性1.4年(1.1,1.8)(P<0.001),6个月EULAR良好/中度缓解的校正OR=3.2(1.6,6.1)(男性 vs 女性)。结论认为男性性别与TNFI治疗有效性更高强烈相关。
要点
- 男性TNFI中位持续用药3.8年(95%CI:3.0,5.7),女性1.4年(1.1,1.8)(P<0.001)。
- 6个月EULAR良好/中度缓解的校正OR=3.2(1.6,6.1)(男性 vs 女性)。
- 校正基线风险因素后性别与治疗有效性的关系未受影响,提示生物学因素的作用。
核心结论
- 男性性别与TNFI治疗有效性更高强烈相关,校正基线风险因素后该关系未受影响,提示生物学因素可能起作用。
研究设计与样本
- 共纳入1750例银屑病关节炎患者,其中女性935例。
- 采用Cox回归和logistic回归模型分析性别对TNFI持续用药和应答的影响,并校正预先选定的混杂因素,包括临床、实验室和患者报告因素、合并症及生活方式特征。
- 治疗应答按EULAR和ACR标准在3个月和6个月评估。
主要发现
- 基线时女性较男性年龄更大(49岁/47岁),吸烟比例更高(32%/26%),患者报告评分更差(如总体评分71 mm/65 mm),医院诊断焦虑或抑郁(7%/4%)及慢性肺病(7%/3%)比例更高(均P<0.01)。
- 男性TNFI中位持续用药时间3.8年(95%CI:3.0,5.7),女性1.4年(1.1,1.8)(P<0.001)。
- 男性在3个月和6个月达到应答的比值比更高,例如6个月EULAR良好/中度缓解的校正OR=3.2(1.6,6.1)(男性 vs 女性)。
关键数值与推荐
- 治疗应答按EULAR和ACR标准评估。
- 男性TNFI中位持续用药3.8年(95%CI:3.0,5.7),女性1.4年(1.1,1.8)(P<0.001)。
- 6个月EULAR良好/中度缓解的校正OR=3.2(1.6,6.1)(男性 vs 女性)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to investigate gender differences in disease manifestations, patient-reported outcomes, comorbidities and treatment effectiveness among patients with PsA treated with their first TNFα inhibitor (TNFI). METHODS: In this observational cohort study, the DANBIO register provided prospectively collected data on PsA patients who initiated their first TNFI in 2000-15. Comorbidity information was achieved from the Danish Nationwide Patient Register. Response to treatment was assessed according to EULAR and ACR criteria at 3 and 6 months. Cox and logistic regression models analysed the impact of gender on TNFI persistence and response, respectively, while adjusting for a priori selected confounders including clinical-, laboratory- and patient-reported factors, comorbidities and lifestyle characteristics. RESULTS: A total of 1750 PsA patients (935 women) were included. At baseline, women were older (49 years/47 years), more often smokers (32%/26%), had worse patient-reported scores (e.g. global score 71 mm/65 mm) and higher frequencies of hospital-diagnosed anxiety or depression (7%/4%) and chronic pulmonary disease (7%/3%) than men (all P < 0.01). Median TNFI persistence was 3.8 years (95% CI: 3.0, 5.7) in men vs 1.4 (1.1, 1.8) in women (P < 0.001). Men had higher odds of achieving response after 3 and 6 months, for example, adjusted odds ratio = 3.2 (1.6, 6.1) for EULAR good/moderate response (vs women) at 6 months. CONCLUSION: Male gender was strongly associated with greater TNFI treatment effectiveness. Adjustment for baseline risk factors including patient-reported outcomes, disease activity, comorbidities and lifestyle factors did not influence this relationship, which suggests a role of biological factors.
引用
- Højgaard P, Ballegaard C, Cordtz R, et al. Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology (Oxford). 2018. PMID: 29893926. doi:10.1093/rheumatology/key140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。